BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15535304)

  • 1. [Chemotherapy for ovarian cancer--introduction].
    Yamada H; Sugiyama T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():540-5. PubMed ID: 15535304
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical characteristics and therapeutic variations in elderly patients with ovarian cancer].
    Kihana T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():632-5. PubMed ID: 15535322
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy for ovarian cancer--general review].
    Ochiai K
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():517-21. PubMed ID: 15535299
    [No Abstract]   [Full Text] [Related]  

  • 4. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
    Sugiyama T; Yoshizaki A; Hatayama S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors of ovarian cancer].
    Ochiai K
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2014-9. PubMed ID: 17197745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
    Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
    Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
    J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb-IV ovarian carcinoma: cisplatin-paclitaxel vs. carboplatin-paclitaxel. AGO Protocol Ovar-3].
    Mettler L
    Zentralbl Gynakol; 1996; 118(6):379-4. PubMed ID: 8768017
    [No Abstract]   [Full Text] [Related]  

  • 10. Carcinoma erysipeloides from ovarian clear-cell carcinoma.
    Lee HC; Chu CY; Hsiao CH
    J Clin Oncol; 2007 Dec; 25(36):5828-30. PubMed ID: 18089882
    [No Abstract]   [Full Text] [Related]  

  • 11. The management of ovarian cancer.
    Ford M; Murdoch J
    Br J Hosp Med; 1997 Dec; 58(11):581-3. PubMed ID: 10193477
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of chemotherapy for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 19. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: "Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study".
    Markman M
    Gynecol Oncol; 2007 Apr; 105(1):279-80; author reply 280-1. PubMed ID: 17291570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.